MLANA and neoplasm: Although these antigens have been targeted clinically, typically by infusion of clonal or Transgenic (Tg)TCR products specific for MART-1/Melan-A derived peptides presented in a HLA-A*02:01 context, this is associated with severe on-target off-tumour toxicity against healthy melanocytes in the skin, eye and gut, limiting their utility as therapeutic targets [9,10,11].